COGT logo

COGT
Cogent Biosciences Inc

3,180
Mkt Cap
$5.42B
Volume
2.84M
52W High
$43.73
52W Low
$3.72
PE Ratio
-13.84
COGT Fundamentals
Price
$35.41
Prev Close
$33.38
Open
$34.00
50D MA
$37.17
Beta
1.57
Avg. Volume
1.61M
EPS (Annual)
-$2.55
P/B
10.43
Rev/Employee
$0.00
$4,008.57
Loading...
Loading...
News
all
press releases
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Key PointsRTW Investments added 4,124,755 Cogent Biosciences shares in the fourth quarter; the estimated trade size was $115.95 million...
Nasdaq News: Markets·2d ago
News Placeholder
More News
News Placeholder
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
Key PointsKynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million...
Nasdaq News: Markets·2d ago
News Placeholder
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
Key PointsBoone Capital Management sold 945,042 shares of Cogent Biosciences in the fourth quarter...
Nasdaq News: Markets·3d ago
News Placeholder
HC Wainwright Analysts Lift Earnings Estimates for COGT
Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - HC Wainwright lifted their Q1 2026 EPS estimates for shares of Cogent Biosciences in a research note issued on Tuesday, March 17th. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings of ($0.53) per share...
MarketBeat·5d ago
News Placeholder
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
Zacks·6d ago
News Placeholder
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush
Wedbush restated an "outperform" rating and set a $55.00 price target on shares of Cogent Biosciences in a report on Tuesday...
MarketBeat·7d ago
News Placeholder
Cinctive Capital Management LP Buys Shares of 111,058 Cogent Biosciences, Inc. $COGT
Cinctive Capital Management LP purchased a new position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund...
MarketBeat·7d ago
News Placeholder
Boothbay Fund Management LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT
Boothbay Fund Management LLC lessened its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 67.8% in the third quarter, according to the company in its most recent Form...
MarketBeat·7d ago
News Placeholder
Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application
FDA accepts Cogent Biosciences' NDA for bezuclastinib in NonAdvSM. PDUFA date set for Dec 30, 2026. COGT stock rises on the news.read more...
Benzinga·7d ago
News Placeholder
Cogent Biosciences (NASDAQ:COGT) Now Covered by Analysts at Jefferies Financial Group
Jefferies Financial Group started coverage on shares of Cogent Biosciences in a report on Monday. They issued a "buy" rating for the company...
MarketBeat·7d ago
<
1
2
...
>

Latest COGT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.